CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02811497
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:14.999427+00:00
Published At: 2021-04-01T00:00:00+00:00
Record Updated At: 2021-04-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Microsatellite Stable Colorectal Carcinoma", "Platinum Resistant Epithelial Ovarian Cancer Type II", "Estrogen Receptor Positive and HER2 Negative Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-04-01"
protocolSection.identificationModule.nctId: "NCT02811497"
protocolSection.identificationModule.officialTitle: "An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.